GlassScriptPhysician profile
Kelly A Ternes
NPI 1609187020
$3,699.07
in general payments reported to CMS, 2019-2025
32 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $109 · 2021: $250 · 2022: $716 · 2023: $679 · 2024: $285 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Education: $50.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.74 |
| Education | $50.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,206.65 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $515.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $236.50 | 2019-2025 | Vest Therapy Und, Encore |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.21 | 2019-2025 | Ofev |
| Mylan Specialty L.P. | $163.31 | 2019-2024 | Yupelri |
| Insmed, INC. | $159.60 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $157.93 | 2019 | |
| Genzyme Corporation | $120.13 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $104.29 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $98.21 | 2022-2025 | Glassia |
| Genentech USA, INC. | $78.25 | 2019-2023 | Xolair |
| Harmony Biosciences LLC | $71.93 | 2021-2022 | |
| Grifols USA, LLC | $66.27 | 2019-2024 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $64.58 | 2019 | |
| Shire North American Group INC | $55.02 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.28 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $41.48 | 2019-2023 | Opsumit |
| Electromed, INC. | $38.18 | 2023-2025 | Smartvest |
| Amgen INC. | $34.00 | 2025 | |
| Viatris Specialty LLC | $30.88 | 2025 | Yupelri |
| Portola Pharmaceuticals, LLC | $30.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.09 | 2021-2022 | |
| Pulmonx Corporation | $24.15 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Axsome Therapeutics, INC. | $19.28 | 2023 | Sunosi |
| Resmed Corp | $18.17 | 2020 | |
| Advanced Respiratory, INC | $17.32 | 2019 | |
| Verona Pharma, INC. | $16.33 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $16.11 | 2019 | |
| Mallinckrodt Hospital Products INC. | $16.09 | 2020 | |
| Pfizer INC. | $13.73 | 2019 | |
| Tactile Systems Technology INC | $13.32 | 2022 | |
| Csl Behring | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Ternes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.